<h4>Background</h4>Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant digestive tumor with an extremely low 5-year survival rate, and KRAS mutation is its predominant molecular characteristic. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.